北京天科雅生物科技有限公司

天科雅生物科技有限公司是由高層次海、內(nèi)外人才團隊于2016年8月在北京中關(guān)村生命科學(xué)園注冊成立的高新技術(shù)企業(yè)。公司中國總部在北京，目前有重慶天科雅，美國TCRCure Biopharm洛杉磯（LA）和北卡羅來那州（NC）三個研發(fā)和臨床轉(zhuǎn)化中心。公司已經(jīng)完成了由美國和中國的專業(yè)醫(yī)療行業(yè)VC機構(gòu)ETP與分享投資領(lǐng)投的A輪融資，建成了產(chǎn)、學(xué)、研和生物醫(yī)學(xué)技術(shù)相關(guān)的研發(fā)平臺，生產(chǎn)平臺和轉(zhuǎn)化技術(shù)平臺。天科雅是以征服癌癥為使命，致力于幫助病人和醫(yī)生把腫瘤慢病化以至Zui終治愈的生物醫(yī)藥研發(fā)型創(chuàng)新公司。以T細胞為Zui終靶向，本公司專注于腫瘤免疫治療技術(shù)的創(chuàng)新性研發(fā)，以及聯(lián)合治療策略的臨床驗證。并以產(chǎn)業(yè)化引領(lǐng)研發(fā)方向，將前沿免疫治療技術(shù)以可承受的成本推向臨床，盡可能多地為病人與醫(yī)生服務(wù)。公司科學(xué)及臨床團隊匯聚了國內(nèi)外免疫細胞治療領(lǐng)域高生物科技人才。研發(fā)團隊中，碩士及博士高學(xué)歷人才占比80%以上，核心科學(xué)團隊成員來自杜克大學(xué)、斯坦福大學(xué)、南加州大學(xué)等世界院校。已申請4項美國專利和7項中國發(fā)明專利，在Cell、Nature、NatureBiotechonology等國際知名刊物發(fā)表論文數(shù)近百篇。公司圍繞腫瘤免疫細胞治療產(chǎn)品的研發(fā)，已經(jīng)建立，國際水準的四大核心技術(shù)平臺。包括TCR免疫組學(xué)和大數(shù)據(jù)分析平臺；個體化腫瘤抗原特異性TCR的克隆和組裝平臺?；赥細胞生物學(xué)特性的基因改造技術(shù)平臺和工業(yè)化臨床級的病毒轉(zhuǎn)基因載體生產(chǎn)平臺。公司基于四大核心技術(shù)平臺，重點打造了四條核心產(chǎn)品線，主要包括：通用型TCR-T產(chǎn)品線；高端TCR-T定制治療產(chǎn)品線；臨床免疫監(jiān)控及免疫藥效評估試劑盒生產(chǎn)線和記憶型+抗抑制的CAR-T、TCR-T產(chǎn)品線。公司近期推出的產(chǎn)品包括用于宮頸癌和頭頸癌的TCR-T治療產(chǎn)品； 中期將持續(xù)推出用于治療結(jié)直腸癌，肺癌和腦癌的CAR-T和TCR-T產(chǎn)品以及用于用藥指導(dǎo)，病程監(jiān)控和預(yù)后判讀等系列檢測試劑盒；長期規(guī)劃中，將推出用于個體化惡性實體腫瘤精準治療的TCR-T產(chǎn)品，為Zui終預(yù)防和治愈惡性腫瘤提供病人和醫(yī)生用得起，治得好和見效快的系列腫瘤免疫細胞治療產(chǎn)品。公司地址：北京 重慶About TCRCureTCRCure Biopharma LLC was founded in August 2016 by a team of immunologists and cell engineers from both USA and China. TCRCureis headquartered in Beijing, China. Over the course of two years, TCRCure has established two R&D sites in Los Angeles, California and Raleigh, North Carolina, as well as a translational medicine center in Chongqing, China.In 2017, TCRcure successfully closed Series A funding. The investment was led by multiple professional healthcare venture capitols, including Share Capitol and ETP Biomedical Venture Capital. To date, TCRCure has streamlined biotechnology development, vector and cell manufacturing, as well as clinical translation intended for full-fledged immunotherapy services.The ultimate goal of this company is to develop next generation cancer immunotherapies that control tumor progression, convert cancers to chronic but manageable diseases, and eventually lead to cure. Focusing on T cell engineering, TCRCure develops cutting edge therapeutic tools and combinatory regimen for oncological intervention. Emphasizing on clinical outcomes, TCRCure aims to industrialize biotechnologies in cancer immunotherapy to affordable cares for broad ranges of patients.TCRCure encompasses top talents in the field of immunology and cell therapy, with more than 80% of employees having master’s degree or higher. The leadership team features professors from Duke University, University of South California and Stanford University, who have published hundreds of scientific articles in high-profile journals including Cell, Natureand Nature Biotechnology. TCRCure’s dedication in immune cell therapy is supported by four pillars of advanced technology: TCR repertoire analysis and big data mining; high throughput antigen-specific TCR cloning; T cell genetic engineering; GMP-level and-industry scale vector production and immune cell manufacturing. Based on these platforms, TCRCure has established four major pipeline of products: generalizable TCR-T; personalized TCR-T; long-lived and suppression-resilient CAR-T/TCR-T; and, clinical immune monitoring services. TCRCure will soon initiate clinical trials for the treatment of HPV-related cervical and head/neck cancers. In the mid-term, TCRCure will quickly expand pipelines for various indications including colorectal cancer, lung cancer and glioblastoma, as well as companion immune-monitoring services for treatment evaluation. The long-term plan involves the de nova development and manufacture of personalized TCR-T products at an acceptable cost for individual cancer patients.